Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples

Katsuyuki Kiura, Kiyotaka Yoh, Nobuyuki Katakami, Naoyuki Nogami, Kazuo Kasahara, Toshiaki Takahashi, Isamu Okamoto, Mireille Cantarini, Rachel Hodge, Hirohiko Uchida

Research output: Contribution to journalArticle

Abstract

Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Patients were enrolled based on a positive result of T790M by using cytology samples, and received osimertinib 80 mg in tablet form once daily until disease progression or until clinical benefit was no longer observed at the discretion of the investigator. Primary endpoint for efficacy was objective response rate (ORR) by investigator assessment. Twenty-eight Japanese patients were enrolled into the cytology cohort. At data cut-off (February 1, 2016), 12 (43%) were on treatment. Investigator-assessed ORR was 75% (95% confidence interval [CI] 55, 89) and median duration of response was 9.7 months (95% CI 3.8, not calculable [NC]). Median progression-free survival was 8.3 months (95% CI 4.2, NC) and disease control rate was 96% (95% CI 82, 100). The most common all-causality adverse events were paronychia (46%), dry skin (46%), diarrhea (36%) and rash (36%). Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. (ClinicalTrials.gov number NCT01802632).

Original languageEnglish
Pages (from-to)1177-1184
Number of pages8
JournalCancer Science
Volume109
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cell Biology
Mutation
Confidence Intervals
Research Personnel
Early Detection of Cancer
Paronychia
Safety
Exanthema
Causality
Protein-Tyrosine Kinases
Tablets
Disease-Free Survival
Disease Progression
osimertinib
Diarrhea
Skin

Keywords

  • cytology
  • epidermal growth factor receptor
  • non-small cell lung cancer
  • osimertinib
  • T790M

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. / Kiura, Katsuyuki; Yoh, Kiyotaka; Katakami, Nobuyuki; Nogami, Naoyuki; Kasahara, Kazuo; Takahashi, Toshiaki; Okamoto, Isamu; Cantarini, Mireille; Hodge, Rachel; Uchida, Hirohiko.

In: Cancer Science, Vol. 109, No. 4, 01.04.2018, p. 1177-1184.

Research output: Contribution to journalArticle

Kiura, K, Yoh, K, Katakami, N, Nogami, N, Kasahara, K, Takahashi, T, Okamoto, I, Cantarini, M, Hodge, R & Uchida, H 2018, 'Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples', Cancer Science, vol. 109, no. 4, pp. 1177-1184. https://doi.org/10.1111/cas.13511
Kiura, Katsuyuki ; Yoh, Kiyotaka ; Katakami, Nobuyuki ; Nogami, Naoyuki ; Kasahara, Kazuo ; Takahashi, Toshiaki ; Okamoto, Isamu ; Cantarini, Mireille ; Hodge, Rachel ; Uchida, Hirohiko. / Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. In: Cancer Science. 2018 ; Vol. 109, No. 4. pp. 1177-1184.
@article{c6b75f07411346788ee3d9bc8af236a3,
title = "Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples",
abstract = "Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Patients were enrolled based on a positive result of T790M by using cytology samples, and received osimertinib 80 mg in tablet form once daily until disease progression or until clinical benefit was no longer observed at the discretion of the investigator. Primary endpoint for efficacy was objective response rate (ORR) by investigator assessment. Twenty-eight Japanese patients were enrolled into the cytology cohort. At data cut-off (February 1, 2016), 12 (43{\%}) were on treatment. Investigator-assessed ORR was 75{\%} (95{\%} confidence interval [CI] 55, 89) and median duration of response was 9.7 months (95{\%} CI 3.8, not calculable [NC]). Median progression-free survival was 8.3 months (95{\%} CI 4.2, NC) and disease control rate was 96{\%} (95{\%} CI 82, 100). The most common all-causality adverse events were paronychia (46{\%}), dry skin (46{\%}), diarrhea (36{\%}) and rash (36{\%}). Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. (ClinicalTrials.gov number NCT01802632).",
keywords = "cytology, epidermal growth factor receptor, non-small cell lung cancer, osimertinib, T790M",
author = "Katsuyuki Kiura and Kiyotaka Yoh and Nobuyuki Katakami and Naoyuki Nogami and Kazuo Kasahara and Toshiaki Takahashi and Isamu Okamoto and Mireille Cantarini and Rachel Hodge and Hirohiko Uchida",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/cas.13511",
language = "English",
volume = "109",
pages = "1177--1184",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples

AU - Kiura, Katsuyuki

AU - Yoh, Kiyotaka

AU - Katakami, Nobuyuki

AU - Nogami, Naoyuki

AU - Kasahara, Kazuo

AU - Takahashi, Toshiaki

AU - Okamoto, Isamu

AU - Cantarini, Mireille

AU - Hodge, Rachel

AU - Uchida, Hirohiko

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Patients were enrolled based on a positive result of T790M by using cytology samples, and received osimertinib 80 mg in tablet form once daily until disease progression or until clinical benefit was no longer observed at the discretion of the investigator. Primary endpoint for efficacy was objective response rate (ORR) by investigator assessment. Twenty-eight Japanese patients were enrolled into the cytology cohort. At data cut-off (February 1, 2016), 12 (43%) were on treatment. Investigator-assessed ORR was 75% (95% confidence interval [CI] 55, 89) and median duration of response was 9.7 months (95% CI 3.8, not calculable [NC]). Median progression-free survival was 8.3 months (95% CI 4.2, NC) and disease control rate was 96% (95% CI 82, 100). The most common all-causality adverse events were paronychia (46%), dry skin (46%), diarrhea (36%) and rash (36%). Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. (ClinicalTrials.gov number NCT01802632).

AB - Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Patients were enrolled based on a positive result of T790M by using cytology samples, and received osimertinib 80 mg in tablet form once daily until disease progression or until clinical benefit was no longer observed at the discretion of the investigator. Primary endpoint for efficacy was objective response rate (ORR) by investigator assessment. Twenty-eight Japanese patients were enrolled into the cytology cohort. At data cut-off (February 1, 2016), 12 (43%) were on treatment. Investigator-assessed ORR was 75% (95% confidence interval [CI] 55, 89) and median duration of response was 9.7 months (95% CI 3.8, not calculable [NC]). Median progression-free survival was 8.3 months (95% CI 4.2, NC) and disease control rate was 96% (95% CI 82, 100). The most common all-causality adverse events were paronychia (46%), dry skin (46%), diarrhea (36%) and rash (36%). Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation-positive status was determined from cytology samples. (ClinicalTrials.gov number NCT01802632).

KW - cytology

KW - epidermal growth factor receptor

KW - non-small cell lung cancer

KW - osimertinib

KW - T790M

UR - http://www.scopus.com/inward/record.url?scp=85042552172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042552172&partnerID=8YFLogxK

U2 - 10.1111/cas.13511

DO - 10.1111/cas.13511

M3 - Article

VL - 109

SP - 1177

EP - 1184

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 4

ER -